Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CAMP by emailGet an email when CAMP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CAMP, unsubscribe in one click. Privacy
📣 What CAMP Says Is Next
2H 2026 · “The Company expects to initiate a global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026.”
Company press release, May 14, 2026 · SEC filing
second half of 2026 · “CAMP4 expects to advance CMP-002 into a Phase 1/2 clinical trial in individuals with SYNGAP1-related disorder in the second half of 2026.”
Company press release, May 14, 2026 · SEC filing
second half of 2026 · ““Our GLP toxicology studies for CMP-002 are ongoing, and we continue to expect to initiate a global first-in-human Phase 1/2 clinical trial as early as the second half of 2026.”
Company press release, Mar 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CAMP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CAMP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.